New combo therapy aims to keep early lung cancer from returning
NCT ID NCT03446547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the drug durvalumab after precise radiation therapy (SBRT) helps people with early-stage lung cancer stay cancer-free longer. About 106 patients with stage I non-small cell lung cancer who could not have surgery or chose not to were randomly assigned to receive either durvalumab infusions every 4 weeks for a year or just follow-up. The main goal was to see if the drug delays cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC, STAGE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dept of Oncology
Tampere, Finland
-
Dept of Oncology
Vaasa, Finland
-
Dept of Oncology
Oslo, Norway
-
Dept of Oncology
Trondheim, Norway
-
Dept of Oncology
Stockholm, Sweden
-
Dept of pulmonary medicine
Tromsø, Norway
-
Dept of pulmonary medicine
Gävle, Sweden
-
Dept of pulmonary medicine
Linköping, Sweden
-
Dept of pulmonary medicine
Lund, Sweden
-
Dept. of Oncology
Gothenburg, Sweden
-
Dept. of Oncology
Umeå, Sweden
-
Helsinki
Helsinki, Finland
-
Sunderbyn
Luleå, Sweden
-
Turku
Turku, Finland
-
Ålesund
Ålesund, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.